heart
failur
hf
continu
signific
clinic
burden
high
mortal
morbid
wors
oneyear
prognosi
cancer
sever
classif
scheme
hf
howev
common
clinic
approach
involv
classifi
ambulatori
patient
chronic
hf
hf
preserv
reduc
leftventricular
eject
fraction
hfpef
hfref
respect
hfpef
present
account
approxim
hf
diagnos
rise
incid
mortal
morbid
compar
hfref
despit
similar
outcom
appear
hfpef
hfref
repres
distinct
group
mani
pathophysiolog
differ
along
continuum
hf
inde
differenti
respons
therapeut
intervent
two
group
strongli
support
concept
clinic
trial
valid
angiotensinconvert
enzym
inhibitor
acei
angiotensin
iireceptor
blocker
arb
betaadrenerg
receptor
antagonist
betablock
mineralocorticoid
receptor
antagonist
mra
therapeut
hfref
convers
trial
acei
arb
betablock
mra
inhibitor
fail
show
consist
signific
improv
clinic
outcom
patient
hfpef
biomark
studi
differenti
implic
variou
pathway
hf
includ
fibrosi
extracellular
matrix
remodel
oxid
cardiomyocyt
stress
inflamm
recent
report
show
circul
tumor
necrosi
factoralpha
receptor
level
signific
predictor
incid
hf
particular
hfpef
versu
hfref
circul
two
receptor
elev
patient
heart
failur
rel
control
studi
present
herein
expand
previou
work
explor
associ
diastol
dysfunct
heart
failur
sever
plasma
level
well
famili
cytokin
communitybas
cohort
healthi
control
ambulatori
hfpef
hfref
patient
use
welldefin
hf
cohort
set
elucid
element
mechan
drive
hfpef
hfref
novel
find
suggest
elev
plasma
level
receptor
particular
close
link
pathophysiolog
hfpef
hfref
studi
conform
convent
outlin
declar
helsinki
receiv
intern
ethic
board
approv
univers
alberta
calgari
use
human
subject
subject
gave
written
inform
consent
part
prospect
clinic
studi
alberta
heart
heart
failur
etiolog
analysi
research
team
project
communitybas
ambulatori
patient
clinic
diagnos
hf
healthi
age
gendermatch
control
n
consecut
recruit
comprehens
clinic
echocardiograph
biomark
analys
threeyear
period
begin
end
blood
pressur
record
sit
recumb
detail
clinic
data
compil
time
enrol
transthorac
echocardiogram
perform
use
phillip
ultrasound
platform
echocardiogram
interpret
cardiologist
special
echocardiographi
train
blind
clinic
classif
biomark
analys
lvef
assess
use
simpson
biplan
method
disk
hf
patient
adjud
hfref
n
hfpef
n
use
lvef
cutoff
accord
clinic
practic
guidelin
adjud
new
york
heart
associ
nyha
function
class
primari
etiolog
hf
determin
cardiologist
blind
biomark
analys
grade
diastol
dysfunct
perform
blind
member
authorship
team
base
previous
publish
guidelin
la
volum
index
later
e
medial
e
use
binari
classifi
diastol
dysfunct
ea
ratio
averag
ee
ratio
patient
afib
use
ascertain
grade
determin
diastol
dysfunct
diastol
dysfunct
analys
could
perform
due
poor
echocardiograph
visual
hfpef
patient
hfref
patient
hfpef
patient
hfref
patient
exclud
diastol
function
analys
due
presenc
sever
mitral
regurgit
mr
bnp
level
assess
previous
describ
use
aler
triag
reagent
pack
aler
inc
ottawa
read
autom
dxi
immunoanalyz
beckmancoult
fullerton
ca
usa
provinci
heath
laboratori
provinc
alberta
serum
level
creatinin
lipid
profil
avail
studi
subject
health
record
part
clinic
evalu
inclus
criteria
healthi
control
follow
histori
cardiovascular
renal
diseas
hypertens
diabet
atrial
fibril
prescript
antiarrhythm
acei
arb
betablock
digoxin
loop
thiazid
diuret
mra
exclus
criteria
studi
group
follow
age
less
year
known
malign
expect
surviv
time
less
one
year
pregnanc
within
previou
six
month
recent
cardiac
event
includ
acut
mi
decompens
hf
moder
sever
pulmonari
hypertens
sever
mitral
aortic
valvular
stenosi
blood
plasma
analysi
collect
oneday
baselin
enrol
includ
acquisit
echocardiogram
ecg
patient
rest
sit
blood
collect
cool
lithiumheparin
tube
immedi
place
ice
prior
plasma
fraction
deep
freez
commerciallyavail
enzymelink
immunosorb
assay
elisa
kit
catalogu
respect
r
system
mn
usa
use
previous
describ
absorb
measur
nm
wavelength
correct
set
nm
assay
use
spectramax
plate
reader
molecular
devic
ca
usa
detect
rate
elisa
respect
inter
intraassay
coeffici
variat
n
n
n
n
respect
plasma
activ
measur
use
previous
establish
immunofluoresc
protocol
lithium
heparin
anticoagul
plateletfre
plasma
sampl
dilut
final
ratio
plasma
assay
buffer
nacl
sigma
chem
co
mo
usa
mm
trishcl
invitrogen
ca
usa
mm
sigma
chem
co
mo
usa
ph
assay
buffer
made
contain
variou
proteas
inhibitor
captopril
ace
inhibitor
sigma
chem
co
mo
usa
amastatin
aminopeptidas
inhibitor
sigma
chem
co
mo
usa
proteas
inhibitor
cocktail
sigma
chem
co
mo
usa
dissolv
achiev
concentr
bestatin
aminopeptidas
inhibitor
n
transepoxysuccinyl
cystein
proteas
inhibitor
nm
pepstatin
aspartyl
proteas
inhibitor
aebsf
benzenesulfonyl
fluorid
hydrochlorid
serin
proteas
inhibitor
nm
phosphoramidon
neprilysin
inhibitor
nm
aprotinin
serin
proteas
inhibitor
nm
leupeptin
cystein
serin
threonin
proteas
inhibitor
use
proteas
inhibitor
buffer
solut
meant
ensur
fluorogen
substrat
specif
inhibitor
describ
integr
assay
cleav
proteas
natur
present
human
plasma
sampl
incub
dnpquench
mcacontain
fluorogen
substrat
catalogu
r
system
mn
usa
final
concentr
find
fluoresc
increas
due
activ
plasma
sampl
assay
presenc
absenc
specif
linear
inhibitor
catalogu
phoenix
pharmaceut
ca
usa
fluoresc
measur
excit
emiss
set
nm
nm
respect
use
spectramax
plate
reader
molecular
devic
ca
usa
maxim
fluoresc
increas
due
activ
determin
maximum
fluoresc
differ
inhibit
uninhibit
aliquot
normal
standard
curv
mcacontain
fluoresc
peptid
catalogu
bachem
ca
usa
scale
time
measur
plasma
volum
hour
hour
baselin
enzymat
activ
valu
herein
express
pmolhrml
describ
amount
substrat
turn
per
unit
time
per
unit
volum
plasma
inter
intraassay
coeffici
variat
n
respect
continu
data
tabl
express
median
interquartil
rang
iqr
parenthes
continu
data
figur
express
box
whisker
plot
logarithm
scale
account
nonnorm
distribut
box
repres
iqr
median
bisect
line
whisker
repres
minimum
maximum
valu
categor
data
express
percentag
categor
data
compar
use
pearson
chisquar
test
continu
variabl
analyz
categori
compar
use
mannwhitney
u
test
kruskalw
test
mannwhitney
u
test
pairwis
comparison
appropri
associ
categor
factor
continu
covari
circul
inflammatori
marker
test
use
binari
logist
linear
regress
analys
respect
logtransform
inflammatori
marker
level
account
nonnorm
distribut
associ
increas
grade
diastol
dysfunct
nyha
function
class
plasma
biomark
test
use
ordin
logist
regress
analys
logtransform
inflammatori
marker
level
forest
plot
use
graphic
display
result
logist
regress
analys
pvalu
consid
signific
statist
analys
statist
analys
conduct
use
spss
statist
version
ibm
ny
usa
obes
defin
per
criteria
estim
glomerular
filtrat
rate
egfr
calcul
revis
fourvari
modif
diet
renal
diseas
equat
leftventricular
hypertrophi
lvh
defin
leftventricular
mass
index
lvmi
male
femal
per
previous
publish
criteria
demograph
clinic
inform
control
hfpef
hfref
group
display
tabl
studi
hf
patient
popul
recapitul
observ
previou
report
studi
subject
predominantli
white
race
studi
group
tabl
hfpef
patient
older
p
significantli
obes
p
hypertens
hfref
patient
neither
hf
group
differ
gender
ratio
p
histori
diabet
peripher
vascular
diseas
p
atrial
fibril
afib
tabl
interestingli
total
cholesterol
p
triglycerid
p
total
cholesterol
highdens
lipoprotein
hdl
ratio
p
significantli
differ
hf
phenotyp
despit
differ
obes
preval
tabl
ischem
etiolog
preval
hfref
hfpef
group
evidencebas
therapeut
regimen
tabl
importantli
drug
affect
inflamm
compar
use
two
hf
group
nsaid
use
equival
statin
use
significantli
differ
p
tabl
nyha
function
class
distribut
also
significantli
differ
hfpef
hfref
group
tabl
heart
rate
differ
significantli
control
two
hf
group
howev
significantli
greater
number
hfpef
patient
afib
day
studi
hfref
patient
p
tabl
hfref
group
significantli
lower
lvef
compar
control
hfpef
group
hfpef
hfref
greater
lv
posterior
wall
thick
lvpw
p
mass
index
lvmi
p
left
atrial
volum
index
la
volum
index
p
averag
ee
ratio
p
compar
control
tabl
lvpw
p
left
ventricular
end
diastol
systol
dimens
lvedd
lvesd
respect
p
significantli
differ
two
hf
group
tabl
distribut
grade
diastol
dysfunct
also
significantli
differ
p
might
due
high
preval
afib
act
confound
analysi
tabl
significantli
hfref
subject
leftventricular
hypertrophi
lvh
hfpef
subject
p
tabl
compar
control
plasma
level
significantli
elev
hpfef
level
significantli
elev
hfpef
hfref
figur
meanwhil
significantli
differ
control
hf
group
figur
interestingli
significantli
elev
hfpef
rel
hfref
nonsignificantli
elev
hfpef
figur
explor
relationship
age
egfr
sex
obes
lvh
hypertens
diabet
smoke
statu
peripher
vascular
diseas
histori
atrial
fibril
combin
hf
group
tabl
advanc
age
significantli
associ
elev
low
egfr
significantli
associ
elev
addit
two
receptor
tabl
increas
differenti
respons
smoke
statu
comorbid
condit
hypertens
diabet
alway
associ
least
two
covari
associ
covari
tabl
sex
obes
lvh
significantli
associ
inflammatori
marker
tabl
investig
inflammatori
marker
studi
relat
two
clinicallyrelev
commonlyus
ordin
quantif
diseas
statu
hf
grade
diastol
dysfunct
nyha
function
class
investig
associ
use
ordin
logist
regress
analys
elev
significantli
associ
increas
grade
diastol
dysfunct
hfpef
hfref
associ
diastol
dysfunct
either
hf
group
figur
interestingli
elev
level
significantli
associ
increas
nyha
function
class
hpfef
hfref
figur
neither
significantli
associ
diastol
dysfunct
symptom
sever
either
hfpef
hfref
data
shown
la
volum
index
associ
plasma
level
hfpef
r
p
r
p
respect
hfref
r
p
r
p
respect
plasma
level
weakli
significantli
associ
averag
ee
ratio
hfpef
figur
c
hfref
r
p
r
p
respect
given
afib
confound
diastol
dysfunct
analys
investig
associ
la
volum
index
averag
ee
ratio
altern
measur
diastol
function
use
patient
afib
increas
activ
convert
enzym
tace
sheddas
involv
proteolyt
process
tnfr
angiotensinconvert
enzym
might
repres
mechan
increas
circul
tnfr
hf
counterregulatori
homologu
angiotensinconvert
enzym
ace
major
regul
endotheli
function
myocardi
fibrosi
sinc
membranebound
local
tace
pose
limit
assess
level
activ
plasma
measur
plasma
activ
surrog
increas
increas
tace
activ
previou
report
plasma
activ
show
associ
clinic
diagnos
hfref
symptom
sever
worsen
clinic
outcom
hfpef
cohort
plasma
activ
significantli
elev
rel
control
figur
howev
associ
increas
grade
diastol
dysfunct
nyha
class
figur
compar
analysi
healthi
control
hf
patient
preserv
reduc
leftventricular
eject
fraction
found
cohort
recapitul
previou
character
wherebi
hfpef
subject
like
older
hypertens
obes
similarli
afib
preval
hf
group
follow
trend
observ
maggic
metaanalysi
furthermor
primari
etiolog
hf
much
less
like
ischem
hfpef
group
despit
differ
comorbid
age
hf
etiolog
nyha
class
distribut
similar
hfref
hfpef
indic
two
patient
popul
experienc
signific
burden
diseas
addit
group
cardiac
hypertrophi
exhibit
mark
diastol
dysfunct
patient
without
mark
systol
dysfunct
greater
preval
comorbid
might
account
similar
symptom
hfpef
hfref
improv
exercis
capac
cohort
hfpef
patient
exercis
train
regimen
larg
mediat
peripher
improv
suggest
system
compon
hfpef
includ
skelet
muscl
dysregul
inde
recent
model
hfpef
suggest
comorbiditymedi
system
inflamm
result
coronari
microvascular
endotheli
dysfunct
myocardi
hypertrophi
fibrosi
skelet
muscl
dysregul
produc
hfpef
phenotyp
investig
receptor
one
compon
comorbiditydriven
inflamm
includ
nontnffamili
cytokin
comparison
expand
previou
work
hf
data
show
level
significantli
increas
hfpef
rel
control
hfref
significantli
increas
rel
control
hfref
plasma
level
compar
hfpef
hfref
suggest
inflamm
might
point
pathophysiolog
differ
hf
phenotyp
found
low
egfr
hypertens
smoke
statu
histori
atrial
fibril
significantli
associ
elev
level
elev
level
associ
age
low
egfr
hypertens
diabet
pvd
elev
level
associ
age
low
egfr
diabet
atrial
fibril
advanc
age
greater
preval
comorbid
hfpef
popul
could
drive
observ
elev
circul
inflammatori
marker
rel
hfref
inde
noncardiac
comorbid
preval
hfpef
larger
fraction
advers
clinic
outcom
attribut
noncardiac
event
compar
hfref
likewis
increas
inflamm
link
increas
risk
advers
cardiovascular
allcaus
outcom
hf
altogeth
data
congruent
paradigm
hfpef
includ
comorbiditiesdriven
dysregul
signal
find
circul
level
significantli
associ
increas
averag
ee
ratio
grade
diastol
dysfunct
hfpef
hfref
suggest
greater
role
inflamm
cohort
howev
found
level
significantli
associ
increas
nyha
class
hf
phenotyp
show
part
hfref
phenotyp
also
attribut
inflamm
associ
diastol
dysfunct
symptom
hfpef
consist
find
experiment
model
axi
involv
mediat
diverg
effect
implic
advers
cardiac
remodel
adipogenesi
antagon
patholog
effect
also
stimul
angiogenesi
also
mediat
opposit
effect
phospholamban
key
handl
protein
involv
myocardi
relax
increas
circul
level
might
reflect
loss
protect
signal
mechan
due
tissu
shed
therebi
lead
correl
circul
level
diastol
dysfunct
symptom
hfpef
differenti
role
tnfr
might
explain
associ
function
symptom
variabl
respons
mediat
receptor
level
congruent
recent
report
found
strongli
associ
either
hf
phenotyp
howev
marti
et
al
implic
studi
implic
hfpef
key
differ
two
studi
marti
et
al
explor
risk
incid
hf
examin
exist
hf
popul
inde
found
associ
greatest
number
hf
risk
factor
congruent
role
precipit
incid
hfpef
meanwhil
data
show
might
better
biomark
gaug
sever
establish
hfpef
circul
fragment
gener
full
transmembran
protein
activ
tace
hypothes
increas
circul
level
might
reflect
increas
activ
tace
also
substrat
tace
plasma
activ
increas
conjunct
increas
tace
activ
sinc
tace
membranebound
surrog
taceact
measur
plasma
activ
hfpef
patient
rel
healthi
control
previou
work
show
signific
associ
symptom
sever
advers
clinic
outcom
patient
hfref
found
significantli
elev
plasma
activ
hfpef
compar
healthi
control
associ
diastol
dysfunct
symptom
congruent
idea
elev
activ
consequ
driver
hfpef
rather
effector
may
case
hfref
take
data
togeth
previou
report
indic
inflammatori
axi
part
pathogenesi
hfpef
context
failur
antagon
therapeut
tool
hf
data
suggest
downstream
approach
involv
inhibit
potenti
may
repres
effect
therapeut
approach
patient
hfpef
studi
larger
studi
compar
level
receptor
hfpef
versu
hfref
still
rel
small
term
clinic
studi
inde
might
also
inform
respect
differenti
hfpef
hfref
studi
resolv
whether
case
addit
result
report
herein
repres
singl
crosssect
across
healthi
control
hfpef
hfref
patient
followup
measur
includ
outcom
data
studi
longitudin
compon
import
implic
variou
molecul
pathway
pathophysiolog
develop
hf
work
marti
et
al
strong
contribut
final
result
provid
correl
evid
whether
biochem
marker
primari
mediat
hf
syndrom
endeffector
pathogen
process
inde
conglomer
evid
point
toward
interplay
plasma
tissu
level
increas
plasma
level
expens
tissu
tissu
plasma
comparison
subject
necessari
determin
rel
effect
proteolyt
process
chang
express
